News

Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...
TipRanks on MSN11h

Eli Lilly’s New Cancer Therapy Study: A Potential Game-Changer?

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...
Aged Care Insite1h

New Alzheimer’s drug rejected by PBS, patients to pay up to $80k a year

A newly approved Alzheimer’s treatment that can slow progression of the disease won’t be subsidised by the federal government ...